Roche's Actem­ra wins ap­proval for hos­pi­tal­ized Covid pa­tients

Roche up­grad­ed its emer­gency use au­tho­riza­tion for Actem­ra in cer­tain hos­pi­tal­ized Covid-19 pa­tients to a full FDA ap­proval, the com­pa­ny an­nounced Wednes­day, as cas­es climb in the US.

The ap­proval comes rough­ly a year and a half af­ter the mon­o­clon­al an­ti­body treat­ment re­ceived an EUA to treat hos­pi­tal­ized pa­tients 2 years and old­er who are al­so re­ceiv­ing sys­temic cor­ti­cos­teroids and re­quire sup­ple­men­tal oxy­gen, ven­ti­la­tion or life sup­port. While the ap­proval is on­ly for adults, Actem­ra will con­tin­ue to be avail­able for younger pa­tients un­der the EUA.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.